Alnylam Pharmaceuticals Inc
ALNY446.400USD
-3.180-0.71%
Cierre 09/26, 16:00（ET）Cotizaciones retrasadas 15 min
58.47BCap. mercado
PérdidaP/E TTM
Más Datos de Alnylam Pharmaceuticals Inc Compañía
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.
Información de la empresa
Símbolo de cotizaciónALNY
Nombre de la empresaAlnylam Pharmaceuticals Inc
Fecha de salida a bolsaMay 28, 2004
Director ejecutivoDr. Yvonne L. Greenstreet, M.D.
Número de empleados2230
Tipo de seguridadOrdinary Share
Fin del año fiscalMay 28
Dirección675 W Kendall St
CiudadCAMBRIDGE
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal02142-1168
Teléfono16175518200
Sitio Webhttps://www.alnylam.com/
Símbolo de cotizaciónALNY
Fecha de salida a bolsaMay 28, 2004
Director ejecutivoDr. Yvonne L. Greenstreet, M.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Yvonne L. Greenstreet, M.D.
Dr. Yvonne L. Greenstreet, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
56.63K
+14.74%
Mr. Jeffrey V. (Jeff) Poulton
Mr. Jeffrey V. (Jeff) Poulton
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
50.18K
+4.96%
Mr. Tolga Tanguler
Mr. Tolga Tanguler
Chief Commercial Officer
Chief Commercial Officer
25.99K
-7.21%
Mr. Michael W. (Mike) Bonney
Mr. Michael W. (Mike) Bonney
Chief Compliance Officer, Director
Chief Compliance Officer, Director
20.80K
--
Dr. Dennis A. Ausiello, M.D.
Dr. Dennis A. Ausiello, M.D.
Independent Director
Independent Director
4.41K
--
Dr. Margaret A. Hamburg, M.D.
Dr. Margaret A. Hamburg, M.D.
Independent Director
Independent Director
911.00
+569.85%
Ms. Carolyn R. Bertozzi, M.D.
Ms. Carolyn R. Bertozzi, M.D.
Independent Director
Independent Director
775.00
--
Dr. Olivier Brandicourt, M.D.
Dr. Olivier Brandicourt, M.D.
Independent Director
Independent Director
775.00
--
Mr. Peter N. Kellogg
Mr. Peter N. Kellogg
Independent Director
Independent Director
775.00
--
Ms. Colleen F. Reitan
Ms. Colleen F. Reitan
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Yvonne L. Greenstreet, M.D.
Dr. Yvonne L. Greenstreet, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
56.63K
+14.74%
Mr. Jeffrey V. (Jeff) Poulton
Mr. Jeffrey V. (Jeff) Poulton
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
50.18K
+4.96%
Mr. Tolga Tanguler
Mr. Tolga Tanguler
Chief Commercial Officer
Chief Commercial Officer
25.99K
-7.21%
Mr. Michael W. (Mike) Bonney
Mr. Michael W. (Mike) Bonney
Chief Compliance Officer, Director
Chief Compliance Officer, Director
20.80K
--
Dr. Dennis A. Ausiello, M.D.
Dr. Dennis A. Ausiello, M.D.
Independent Director
Independent Director
4.41K
--
Dr. Margaret A. Hamburg, M.D.
Dr. Margaret A. Hamburg, M.D.
Independent Director
Independent Director
911.00
+569.85%
Desglose de ingresos
Divisa: USDActualizado: dom., 6 de jul
Divisa: USDActualizado: dom., 6 de jul
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
Por negocioUSD
Nombre
Ganancia
Proporción
AMVUTTRA
309.99M
52.17%
GIVLAARI
66.97M
11.27%
Other
57.56M
9.69%
Regeneron Pharmaceuticals
51.04M
8.59%
ONPATTRO
49.49M
8.33%
Otro
59.15M
9.95%
Por regiónUSD
Nombre
Ganancia
Proporción
United States
271.44M
45.68%
Europe
146.16M
24.60%
Net revenues from collaborations
99.19M
16.69%
Rest of World
50.94M
8.57%
Royalty revenue
26.47M
4.45%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
AMVUTTRA
309.99M
52.17%
GIVLAARI
66.97M
11.27%
Other
57.56M
9.69%
Regeneron Pharmaceuticals
51.04M
8.59%
ONPATTRO
49.49M
8.33%
Otro
59.15M
9.95%
Estadísticas de accionistas
Actualizado: sáb., 16 de ago
Actualizado: sáb., 16 de ago
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Capital World Investors
12.82%
Fidelity Management & Research Company LLC
11.48%
The Vanguard Group, Inc.
10.10%
Capital Research Global Investors
5.49%
BlackRock Institutional Trust Company, N.A.
4.98%
Otro
55.13%
Accionistas
Accionistas
Proporción
Capital World Investors
12.82%
Fidelity Management & Research Company LLC
11.48%
The Vanguard Group, Inc.
10.10%
Capital Research Global Investors
5.49%
BlackRock Institutional Trust Company, N.A.
4.98%
Otro
55.13%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
67.79%
Investment Advisor/Hedge Fund
21.50%
Hedge Fund
3.75%
Corporation
3.39%
Research Firm
1.74%
Sovereign Wealth Fund
1.65%
Pension Fund
1.31%
Bank and Trust
1.08%
Individual Investor
0.40%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
1300
131.78M
100.54%
-3.28M
2025Q1
1315
132.55M
101.67%
-2.42M
2024Q4
1263
130.73M
100.99%
-1.47M
2024Q3
1225
126.90M
98.51%
-1.26M
2024Q2
1183
123.30M
96.32%
+1.12M
2024Q1
1172
117.88M
93.23%
-5.46M
2023Q4
1169
120.70M
96.18%
-5.54M
2023Q3
1125
121.55M
96.89%
-6.15M
2023Q2
1119
122.11M
98.30%
-6.32M
2023Q1
1116
123.13M
99.37%
-5.56M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Capital World Investors
16.75M
12.85%
+149.10K
+0.90%
Mar 31, 2025
Fidelity Management & Research Company LLC
14.62M
11.22%
+1.68M
+13.00%
Mar 31, 2025
The Vanguard Group, Inc.
13.00M
9.97%
+322.72K
+2.55%
Mar 31, 2025
Capital Research Global Investors
7.15M
5.49%
+186.22K
+2.67%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
6.73M
5.16%
-22.21K
-0.33%
Mar 31, 2025
Regeneron Pharmaceuticals Inc
4.44M
3.41%
--
--
Mar 31, 2025
T. Rowe Price Investment Management, Inc.
4.42M
3.39%
+33.70K
+0.77%
Mar 31, 2025
Dodge & Cox
3.35M
2.57%
-188.50K
-5.32%
Mar 31, 2025
State Street Global Advisors (US)
3.37M
2.58%
-56.29K
-1.64%
Mar 31, 2025
T. Rowe Price Associates, Inc.
3.41M
2.61%
+178.26K
+5.52%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de sep
Actualizado: sáb., 6 de sep
Nombre
Proporción
Invesco Biotechnology & Genome ETF
7.04%
VanEck Biotech ETF
6.46%
Global X Genomics & Biotechnology ETF
6.23%
Invesco Nasdaq Biotechnology ETF
5.46%
iShares Biotechnology ETF
5.37%
ProShares Ultra Nasdaq Biotechnology
4.76%
First Trust NYSE Arca Biotechnology Index Fund
4.75%
Franklin Genomic Advancements ETF
4.69%
SPDR S&P Biotech ETF
3.66%
Simplify Next Intangible Core Index ETF
3.6%
Ver más
Invesco Biotechnology & Genome ETF
Proporción7.04%
VanEck Biotech ETF
Proporción6.46%
Global X Genomics & Biotechnology ETF
Proporción6.23%
Invesco Nasdaq Biotechnology ETF
Proporción5.46%
iShares Biotechnology ETF
Proporción5.37%
ProShares Ultra Nasdaq Biotechnology
Proporción4.76%
First Trust NYSE Arca Biotechnology Index Fund
Proporción4.75%
Franklin Genomic Advancements ETF
Proporción4.69%
SPDR S&P Biotech ETF
Proporción3.66%
Simplify Next Intangible Core Index ETF
Proporción3.6%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
